{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T12:00:20Z","timestamp":1722945620103},"reference-count":21,"publisher":"The University of Occupational and Environmental Health, Japan","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J UOEH"],"published-print":{"date-parts":[[2022,9,1]]},"DOI":"10.7888\/juoeh.44.277","type":"journal-article","created":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T22:15:47Z","timestamp":1662675347000},"page":"277-286","source":"Crossref","is-referenced-by-count":1,"title":["A Case Report of Primary Unresectable Hilar Cholangiocarcinoma Causing Colonic Obstruction Due to Peritoneal Dissemination"],"prefix":"10.7888","volume":"44","author":[{"given":"Atsushi","family":"TOYOFUKU","sequence":"first","affiliation":[{"name":"Department of General Surgery, Kitakyushu General Hospital."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"KURODA","sequence":"additional","affiliation":[{"name":"Department of Emergency, Kitakyushu General Hospital."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuma","family":"ITO","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Kitakyushu General Hospital."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akiko","family":"SAKURAI","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Kitakyushu General Hospital."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"YOSHIDA","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Kitakyushu General Hospital."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aiichiro","family":"HIGURE","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Kitakyushu General Hospital."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinsaku","family":"YAMAGUCHI","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kitakyushu General Hospital."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"YOTSUMOTO","sequence":"additional","affiliation":[{"name":"Department of Radiology, Kitakyushu General Hospital."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken-ichi","family":"SAKITA","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kitakyushu General Hospital."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"NAGATA","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Kitakyushu General Hospital."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4637","reference":[{"key":"1","unstructured":"1 . National Cancer Center, Japan : Cancer Statistics.  Cancer Information Service.\nhttps:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/index.html#a14(accessed January 10, 2022) (in Japanese)"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 . Matsuda T, Ajiki W, Marugame T<i> et al<\/i> (2010): Population-based survival of cancer patients diagnosed between 1993 and 1999 in Japan: A chronological and international comparative study.  Japanese Journal of Clinical Oncology 41 (1): 40\u221251 (in Japanese)","DOI":"10.1093\/jjco\/hyq167"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 . Patel T (2011): Cholangiocarcinoma-controversies and challenges.  Nat Rev Gastroenterol & Hepatol 8 (4): 189\u2212200","DOI":"10.1038\/nrgastro.2011.20"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 . Valle J, Wasan H, Palmer DH<i> et al<\/i> (2010): Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.  N Engl J Med 362 (14): 1273\u22121281","DOI":"10.1056\/NEJMoa0908721"},{"key":"5","unstructured":"5 . Peixoto RD, Renouf D & Lim H (2014): A population based analysis of prognostic factors in advanced biliary tract cancer.  J Gastrointest Oncol 5 (6): 428\u2212432"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 . Shinchi H, Takao S, Nishida H & Aikou T (2000): Length and quality of survival following external beam radiotherapy combined with expandable metallic stent for unresectable hilar cholangiocarcinoma.  J Surg Oncol 75 (2): 89\u221294","DOI":"10.1002\/1096-9098(200010)75:2<89::AID-JSO3>3.0.CO;2-V"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 . Shinohara ET, Mitra N, Guo M & Metz JM (2009): Radiotherapy is associated with improved survival in adjuvant and palliative treatment of extrahepatic cholangiocarcinomas.  Int J Radiat Oncol Biol Phys 74 (4): 1191\u22121198","DOI":"10.1016\/j.ijrobp.2008.09.017"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 . V\u00e1lek V, Kysela P, Kala Z, Kiss I, Tom\u00e1\u0161ek J & Petera J (2007): Brachytherapy and percutaneous stenting in the treatment of cholangiocarcinoma: A prospective randomised study.  European Journal of Radiology 62 (2): 175\u2212179","DOI":"10.1016\/j.ejrad.2007.01.037"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 . Nagino M, Hirano S, Yoshitomi H<i> et al<\/i> (2021): Clinical practice guidelines for the management of biliary tract cancers 2019: The 3rd English edition.  J Hepatobiliary Pancreat Sci 28 (1): 26\u221254","DOI":"10.1002\/jhbp.870"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 . Valle J, Wasan H, Palmer DH<i> et al<\/i> (2010): Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer.  N Engl J Med 362 (14): 1273\u22121281","DOI":"10.1056\/NEJMoa0908721"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 . Morizane C, Okusaka T, Mizusawa J<i> et al<\/i> (2019): Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced\/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial.  Ann Oncol 30 (12): 1950\u22121958","DOI":"10.1093\/annonc\/mdz402"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 . Sakai D, Kanai M, Kobayashi S<i> et al<\/i> (2018): Randomized phase III study of gemcitabine, cisplatin plus S-1 (GCS) versus gemcitabine, cisplatin (GC) for advanced biliary tract cancer (KHBO1401-MITSUBA).  Annals of Oncology 29: viii205","DOI":"10.1093\/annonc\/mdy282"},{"key":"13","unstructured":"13 . National Comprehensive Cancer Network (2021): NCCN Clinical Practice Guidelines in Oncology.  Hepatobiliary Cancers (version 5).  https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hepatobiliary.pdf (accessed February 4, 2022)"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 . Foo ML, Gunderson LL, Bender CE & Buskirk SJ (1997): External radiation therapy and transcatheter iridium in the treatment of extrahepatic bile duct carcinoma.  Int J of Radiat Oncol Biol Phys 39 (4): 929\u2212935","DOI":"10.1016\/S0360-3016(97)00299-X"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 . Lin LL, Picus J, Drebin JA<i> et al<\/i> (2005): A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma.  Am J Clin Oncol 28 (3): 234\u2212241","DOI":"10.1097\/01.coc.0000156920.11091.12"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 . Park JY, Park SW, Chung JB<i> et al<\/i> (2006): Concurrent chemoradiotherapy with doxifluridine and paclitaxel for extrahepatic bile duct cancer.  Am J Clin Oncol 29 (3): 240\u2212245","DOI":"10.1097\/01.coc.0000217829.77404.22"},{"key":"17","unstructured":"17 . Autorino R, Mattiucci GC, Ardito F<i> et al<\/i> (2016): Radiochemotherapy with gemcitabine in unresectable extrahepatic cholangiocarcinoma: Long-term results of a phase II study.  Anticancer Res 36 (2): 737\u2212740"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 . Lee KJ, Yi SW, Cha J<i> et al<\/i> (2016): A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer.  Cancer Chemother Pharmacol 78 (4): 841\u2212846","DOI":"10.1007\/s00280-016-3143-2"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 . Mano H (2020): Cancer genomic medicine in Japan.  Proc Jpn Acad Ser B Phy Biol Sci 96 (7): 316\u2212320","DOI":"10.2183\/pjab.96.023"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 . Nakamura H, Arai Y, Totoki Y<i> et al<\/i> (2015): Genomic spectra of biliary tract cancer.  Nat Genet 47 (9): 1003\u22121010","DOI":"10.1038\/ng.3375"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 . Wardell CP, Fujita M, Yamada T<i> et al<\/i> (2018): Genomic characterization of biliary tract cancers identifies driver genes and predisposing mutations.  J Hepatol 68 (5): 959\u2212969","DOI":"10.1016\/j.jhep.2018.01.009"}],"container-title":["Journal of UOEH"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/juoeh\/44\/3\/44_277\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,10]],"date-time":"2022-09-10T05:05:10Z","timestamp":1662786310000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/juoeh\/44\/3\/44_277\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.7888\/juoeh.44.277","relation":{},"ISSN":["0387-821X","2187-2864"],"issn-type":[{"value":"0387-821X","type":"print"},{"value":"2187-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]}}}